Manager × security

DCF Advisers, LLC REGN holdings history

Who else holds this security? →

REGENERON PHARMACEUTICALS · CUSIP 75886F107 · CIK 1802493

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, DCF Advisers, LLC reported 9.25K REGN (shares), valued at $5.77M, or 1.51% of its reported non-derivative portfolio. Filed 2026-08-10.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
1.51%
Shares
9.25K
9,250
Reported value
$5.77M
USD

Shares unchanged; reported value decreased 19.30%, and weight changed -1.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20261.51%9,250SEC filing ↗Filed Aug 10, 2026
Q1 20262.69%9,250SEC filing ↗Filed May 11, 2026
Q4 20252.55%10,000SEC filing ↗Filed Feb 11, 2026
Q3 20252.13%10,000SEC filing ↗Filed Nov 12, 2025
Q2 20252.37%9,400SEC filing ↗Filed Aug 12, 2025
Q1 20253.03%8,900SEC filing ↗Filed May 9, 2025
Q4 20243.20%8,900SEC filing ↗Filed Feb 11, 2025
Q3 20244.20%7,750SEC filing ↗Filed Nov 13, 2024
Q2 20245.71%10,400SEC filing ↗Filed Aug 12, 2024
Q1 20246.15%10,600SEC filing ↗Filed May 15, 2024
Q4 20237.26%12,200SEC filing ↗Filed Feb 13, 2024
Q3 20236.24%10,875SEC filing ↗Filed Nov 13, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20236.24%10,875$8.95MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 13, 2023
Q4 20237.26%12,200$10.72MShares increased 12.18%; reported value increased 19.73%, and weight changed +1.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2024
Q1 20246.15%10,600$10.20MShares decreased 13.11%; reported value decreased 4.79%, and weight changed -1.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20245.71%10,400$10.93MShares decreased 1.89%; reported value increased 7.14%, and weight changed -0.44 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2024
Q3 20244.20%7,750$8.15MShares decreased 25.48%; reported value decreased 25.47%, and weight changed -1.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 20243.20%8,900$6.34MShares increased 14.84%; reported value decreased 22.18%, and weight changed -1.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 11, 2025
Q1 20253.03%8,900$5.64MShares unchanged; reported value decreased 10.96%, and weight changed -0.17 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 9, 2025
Q2 20252.37%9,400$4.93MShares increased 5.62%; reported value decreased 12.57%, and weight changed -0.66 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2025
Q3 20252.13%10,000$5.62MShares increased 6.38%; reported value increased 13.94%, and weight changed -0.24 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 12, 2025
Q4 20252.55%10,000$7.72MShares unchanged; reported value increased 37.28%, and weight changed +0.42 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 11, 2026
Q1 20262.69%9,250$7.15MShares decreased 7.50%; reported value decreased 7.41%, and weight changed +0.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 11, 2026
Q2 20261.51%9,250$5.77MShares unchanged; reported value decreased 19.30%, and weight changed -1.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 10, 2026
DCF Advisers, LLC · REGENERON PHARMACEUTICALS

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1802493","quarter":"2026Q2","cusip":"75886F107"}

get_institutional_manager_history
{"cik":"1802493","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.